ARYx Therapeutics, Inc.
Net BuyingARYX·US·🇺🇸 US
84%buys·16%sales
275 transactions$114.2MTotal buys·84 buys
$20.4MTotal sells·16 sells
4646 insiders
Last: Mar 10, 2011
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Mar 10, 11 | KERINS PATRICK J | Sell | $313K | |
| Mar 10, 11 | KOLLURI KRISHNA KITTU | Sell | $313K | |
| Mar 10, 11 | BASKETT FOREST | Sell | $313K | |
| Mar 10, 11 | DRANT RYAN D | Sell | $313K | |
| Mar 10, 11 | NEA 12 GP, LLC | Sell | $313K | |
| Mar 10, 11 | New Enterprise Associates 12, Limited Partnership | Sell | $313K | |
| Mar 10, 11 | PERRY MARK W | Sell | $313K | |
| Mar 10, 11 | BARRIS PETER J | Sell | $313K | |
| Mar 10, 11 | NEA Partners 12, Limited Partnership | Sell | $313K | |
| Mar 10, 11 | BARRETT M JAMES | Sell | $313K |
ARYx Therapeutics, Inc. is seeing coordinated insider selling. 10 insiders sold shares in the last 30 days, with total sell volume of $3.1M. Overall insider sentiment is bullish (84% purchases).
ARYx Therapeutics, Inc. (ARYX) has recorded 275 insider operations, including 84 open-market purchases ($114.2M), 16 sales ($20.4M) and 175 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bullish (84% purchases).
ARYx Therapeutics, Inc. shows moderate insider activity with 4 active months out of the last 12, typical of a company whose trading windows are concentrated around financial disclosures.
Among the most active insiders are GODDARD PAUL (CEO), Varian John (CFO) & Druzgala Pascal (C SUITE), with respectively 133, 170, 9 transactions.
Across all 275 recorded transactions, the breakdown by type is: exercise (130, 47%), buys (84, 31%), grant (39, 14%), sales (16, 6%), other (4, 1%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
ARYx Therapeutics, Inc. has recorded 275 insider operations in total, including 84 open-market purchases ($114.2M), 16 sales ($20.4M) and 175 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on March 10, 2011.
Insiders at ARYx Therapeutics, Inc. are currently net buyers, with 84% purchases and 16% sales across all reported transactions. Total buy volume is $114.2M versus $20.4M in sales, indicating a bullish insider sentiment.
InsiderLens tracks 46 insiders at ARYx Therapeutics, Inc. (ARYX). GODDARD PAUL (CEO, 133 tx), Varian John (CFO, 170 tx), Druzgala Pascal (C SUITE, 9 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for ARYX is bullish, based on a 84% buy ratio across 100 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for ARYx Therapeutics, Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.